{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:08:57Z","timestamp":1760148537340,"version":"build-2065373602"},"reference-count":80,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DOD\u2019s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)","award":["MCDC 18-05-19-002"],"award-info":[{"award-number":["MCDC 18-05-19-002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB\/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human.<\/jats:p>","DOI":"10.3390\/antib12020033","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T01:06:28Z","timestamp":1683594388000},"page":"33","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague"],"prefix":"10.3390","volume":"12","author":[{"given":"Sergei S.","family":"Biryukov","sequence":"first","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"SAB Biotherapeutics, 2100 E 54th St. N, Sioux Falls, SD 57104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Dankmeyer","sequence":"additional","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel O.","family":"Rill","sequence":"additional","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Klimko","sequence":"additional","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi A.","family":"Egland","sequence":"additional","affiliation":[{"name":"SAB Biotherapeutics, 2100 E 54th St. N, Sioux Falls, SD 57104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Shoe","sequence":"additional","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Hunter","sequence":"additional","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Fetterer","sequence":"additional","affiliation":[{"name":"Biostatistics Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Qiu","sequence":"additional","affiliation":[{"name":"Biostatistics Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-6448","authenticated-orcid":false,"given":"Michael L.","family":"Davies","sequence":"additional","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph L.","family":"Bausch","sequence":"additional","affiliation":[{"name":"SAB Biotherapeutics, 2100 E 54th St. N, Sioux Falls, SD 57104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"SAB Biotherapeutics, 2100 E 54th St. N, Sioux Falls, SD 57104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Luke","sequence":"additional","affiliation":[{"name":"SAB Biotherapeutics, 2100 E 54th St. N, Sioux Falls, SD 57104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher K.","family":"Cote","sequence":"additional","affiliation":[{"name":"Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rosario-Acevedo, R., Biryukov, S.S., Bozue, J.A., and Cote, C.K. (2021). Plague Prevention and Therapy: Perspectives on Current and Future Strategies. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101421"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.micinf.2019.06.007","article-title":"Yersinia pestis and plague: An updated view on evolution, virulence determinants, immune subversion, vaccination and diagnostics","volume":"21","author":"Demeure","year":"2019","journal-title":"Microbes Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1042\/bst0310104","article-title":"Yersinia pestis and plague","volume":"31","author":"Titball","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tim.2015.11.008","article-title":"Pneumonic plague: The darker side of Yersinia pestis","volume":"24","author":"Pechous","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.spid.2006.07.002","article-title":"Plague: A review of its history and potential as a biological weapon","volume":"17","author":"Ligon","year":"2006","journal-title":"Semin. Pediatr. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/ciz1227","article-title":"Antimicrobial Treatment Patterns and Illness Outcome Among United States Patients with Plague, 1942\u20132018","volume":"70","author":"Kugeler","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/cid\/ciz1230","article-title":"Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939\u20132019","volume":"70","author":"Cooley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.24171\/j.phrp.2021.0288","article-title":"Yersinia pestis antibiotic resistance: A systematic review","volume":"13","author":"Lei","year":"2022","journal-title":"Osong Public Health Res. Perspect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/cid\/ciab606","article-title":"Transmission of antimicrobial resistant Yersinia pestis during a pneumonic plague outbreak","volume":"74","author":"Andrianaivoarimanana","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1099\/jmm.0.000915","article-title":"The rise of pneumonic plague in Madagascar: Current plague outbreak breaks usual seasonal mould","volume":"68","author":"Rabaan","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijantimicag.2017.09.015","article-title":"Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat","volume":"51","author":"Cabanel","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2958.2002.03159.x","article-title":"High-frequency conjugative transfer of antibiotic resistance genes to Yersinia pestis in the flea midgut","volume":"46","author":"Hinnebusch","year":"2002","journal-title":"Mol. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3201\/eid0701.010106","article-title":"Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis","volume":"7","author":"Guiyoule","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12044","article-title":"Protecting against plague: Towards a next-generation vaccine","volume":"172","author":"Williamson","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.vaccine.2009.10.143","article-title":"Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice","volume":"28","author":"Little","year":"2010","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0014-5793(90)80852-A","article-title":"Nucleotide sequence of the Yersinia pestis gene encoding F1 antigen and the primary structure of the protein. Putative T and B cell epitopes","volume":"277","author":"Galyov","year":"1990","journal-title":"FEBS Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1348-0421.2004.tb03605.x","article-title":"Microarray analysis of temperature-induced transcriptome of Yersinia pestis","volume":"48","author":"Han","year":"2004","journal-title":"Microbiol. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.70.3.1453-1460.2002","article-title":"Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis","volume":"70","author":"Du","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4049\/jimmunol.83.4.348","article-title":"The role of multiplication of Pasteurella pestis in mononuclear phagocytes in the pathogenesis of flea-borne plague","volume":"83","author":"Cavanaugh","year":"1959","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1756-3305-4-191","article-title":"Effects of temperature on the transmission of Yersinia pestis by the flea, Xenopsylla cheopis, in the late phase period","volume":"4","author":"Schotthoefer","year":"2011","journal-title":"Parasit Vectors"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1128\/IAI.00612-06","article-title":"Effects of Psa and F1 on the adhesive and invasive interactions of Yersinia pestis with human respiratory tract epithelial cells","volume":"74","author":"Liu","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1128\/IAI.67.3.1533-1537.1999","article-title":"Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis","volume":"67","author":"Andrews","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/IAI.00189-08","article-title":"Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestis","volume":"76","author":"Ivanov","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_24","first-page":"325","article-title":"Construction of defined F1 negative mutants of virulent Yersinia pestis","volume":"13","author":"Worsham","year":"1995","journal-title":"Contrib. Microbiol. Immunol."},{"key":"ref_25","first-page":"299","article-title":"Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis","volume":"13","author":"Welkos","year":"1995","journal-title":"Contrib. Microbiol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"726416","DOI":"10.3389\/fimmu.2021.726416","article-title":"Impact of Toll-like receptor-specific agonists on the host immune response to the Yersinia pestis plague rF1V vaccine","volume":"12","author":"Biryukov","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-695X.1995.tb00196.x","article-title":"A new improved sub-unit vaccine for plague: The basis of protection","volume":"12","author":"Williamson","year":"1995","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/iai.64.11.4580-4585.1996","article-title":"Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis","volume":"64","author":"Anderson","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1365-2958.1999.01408.x","article-title":"The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation","volume":"32","author":"Pettersson","year":"1999","journal-title":"Mol. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tim.2006.02.010","article-title":"Type III secretion gets an LcrV tip","volume":"14","author":"Mota","year":"2006","journal-title":"Trends Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/mpat.2002.0498","article-title":"Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis","volume":"32","author":"Weeks","year":"2002","journal-title":"Microb. Pathog."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1128\/IAI.73.9.6127-6137.2005","article-title":"Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis","volume":"73","author":"Cowan","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/CVI.00333-09","article-title":"Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague","volume":"16","author":"Eisele","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2004.07.013","article-title":"Turning Yersinia pathogenesis outside in: Subversion of macrophage function by intracellular Yersiniae","volume":"114","author":"Pujol","year":"2005","journal-title":"Clin Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"DiMezzo, T.L., Ruthel, G., Brueggemann, E.E., Hines, H.B., Ribot, W.J., Chapman, C.E., Powell, B.S., and Welkos, S.L. (2009). In vitro intracellular trafficking of virulence antigen during infection by Yersinia pestis. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006281"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/mpat.1997.0188","article-title":"V antigen of Yersinia pestis inhibits neutrophil chemotaxis","volume":"24","author":"Welkos","year":"1998","journal-title":"Microb. Pathog."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1128\/iai.65.11.4476-4482.1997","article-title":"Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization","volume":"65","author":"Hill","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.meegid.2009.10.003","article-title":"Amino acid and structural variability of Yersinia pestis LcrV protein","volume":"10","author":"Anisimov","year":"2010","journal-title":"Infect. Genet. Evol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/iai.65.2.446-451.1997","article-title":"Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen","volume":"65","author":"Roggenkamp","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2019.01830","article-title":"Polymorphism in the Yersinia LcrV antigen enables immune escape from the protection conferred by an LcrV-secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model","volume":"2","author":"Daniel","year":"2019","journal-title":"Front Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1016\/j.vaccine.2011.04.084","article-title":"Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague","volume":"29","author":"Williamson","year":"2011","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pep.2010.10.011","article-title":"Purification and characterization of a recombinant Yersinia pestis V-F1 \u201cReversed\u201d fusion protein for use as a new subunit vaccine against plague","volume":"76","author":"Goodin","year":"2011","journal-title":"Protein Expr. Purif."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.micpath.2006.09.003","article-title":"Immunogenicity of the rF1+ rV vaccine for plague with identification of potential immune correlates","volume":"42","author":"Williamson","year":"2007","journal-title":"Microb. Pathog."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.vaccine.2006.09.052","article-title":"Kinetics of the immune response to the (F1+ V) vaccine in models of bubonic and pneumonic plague","volume":"25","author":"Williamson","year":"2007","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1128\/IAI.73.6.3598-3608.2005","article-title":"Human immune response to a plague vaccine comprising recombinant F1 and V antigens","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/IAI.71.4.2234-2238.2003","article-title":"Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis","volume":"71","author":"Hill","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Xiao, X., Zhu, Z., Dankmeyer, J.L., Wormald, M.M., Fast, R.L., Worsham, P.L., Cote, C.K., Amemiya, K., and Dimitrov, D.S. (2010). Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013047"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.1997.56.471","article-title":"Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis","volume":"56","author":"Anderson","year":"1997","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.vaccine.2008.01.033","article-title":"Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague","volume":"26","author":"Zauberman","year":"2008","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7748","DOI":"10.1016\/j.vaccine.2010.09.062","article-title":"Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)","volume":"28","author":"Fellows","year":"2010","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1093\/clinids\/21.Supplement_2.S178","article-title":"Relationship between virulence and immunity as revealed in recent studies of the Fl capsule of Yersinia pestis","volume":"21","author":"Friedlander","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"807564","DOI":"10.1155\/2014\/807564","article-title":"Efficacy of primate humoral passive transfer in a murine model of pneumonic plague is mouse strain-dependent","volume":"2014","author":"Graham","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/iai.62.10.4192-4201.1994","article-title":"Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein AV antigen fusion peptide","volume":"62","author":"Motin","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4049\/jimmunol.88.2.153","article-title":"Studies on the immune response of guinea pigs to the envelope substance of Pasteurella pestis. I. Immunogenicity and persistence of large doses of fraction I in guinea pigs observed with fluorescent antibody","volume":"88","author":"Walker","year":"1962","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1128\/IAI.74.5.3068-3070.2006","article-title":"Administration of antibody to the lung protects mice against pneumonic plague","volume":"74","author":"Hill","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00226-17","DOI":"10.1128\/JVI.00226-17","article-title":"Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus","volume":"91","author":"Gardner","year":"2017","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Gilliland, T., Liu, Y., Li, R., Dunn, M., Cottle, E., Terada, Y., Ryckman, Z., Alcorn, M., Vasilatos, S., and Lundy, J. (2021). Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines. bioRxiv.","DOI":"10.1101\/2021.07.26.453840"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1940652","DOI":"10.1080\/21645515.2021.1940652","article-title":"Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants","volume":"18","author":"Liu","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1093\/infdis\/jiy377","article-title":"Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate","volume":"218","author":"Luke","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"326ra321","DOI":"10.1126\/scitranslmed.aaf1061","article-title":"Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo","volume":"8","author":"Luke","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3389\/fmicb.2020.00832","article-title":"Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models","volume":"11","author":"Perley","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/S0264-410X(02)00119-6","article-title":"Determination of the virulence of the pigmentation-deficient and pigmentation-\/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague","volume":"20","author":"Welkos","year":"2002","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4269\/ajtmh.1994.51.109","article-title":"Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona","volume":"51","author":"Doll","year":"1994","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Matsushita, H., Sano, A., Wu, H., Jiao, J.A., Kasinathan, P., Sullivan, E.J., Wang, Z., and Kuroiwa, Y. (2014). Triple immunoglobulin gene knockout transchromosomic cattle: Bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090383"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Matsushita, H., Sano, A., Wu, H., Wang, Z., Jiao, J.A., Kasinathan, P., Sullivan, E.J., and Kuroiwa, Y. (2015). Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130699"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"24897","DOI":"10.1038\/srep24897","article-title":"Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle","volume":"6","author":"Dye","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/iai.56.8.2139-2143.1988","article-title":"Inhibition of phagocytosis in Yersinia pseudotuberculosis: A virulence plasmid-encoded ability involving the Yop2b protein","volume":"56","author":"Rosqvist","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jmb.2007.07.077","article-title":"Induction of the Yersinia type 3 secretion system as an all-or-none phenomenon","volume":"373","author":"Wiley","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Bozue, J., Cote, C.K., Chance, T., Kugelman, J., Kern, S.J., Kijek, T.K., Jenkins, A., Mou, S., Moody, K., and Fritz, D. (2014). A Yersinia pestis tat mutant is attenuated in bubonic and small-aerosol pneumonic challenge models of infection but not as attenuated by intranasal challenge. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104524"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1574-6968.2012.02583.x","article-title":"A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice","volume":"332","author":"Bozue","year":"2012","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1086\/520547","article-title":"Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague","volume":"196","author":"Heine","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3389\/fimmu.2017.01175","article-title":"Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein","volume":"8","author":"Maeda","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Amemiya, K., Dankmeyer, J.L., Keasey, S.L., Trevino, S.R., Wormald, M.M., Halasohoris, S.A., Ribot, W.J., Fetterer, D.P., Cote, C.K., and Worsham, P.L. (2020). Binding Sites of Anti-Lcr V Monoclonal Antibodies Are More Critical than the Avidities and Affinities for Passive Protection against Yersinia pestis Infection in a Bubonic Plague Model. Antibodies, 9.","DOI":"10.3390\/antib9030037"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-0-387-72124-8_3","article-title":"Variability of the protein sequences of lcrV between epidemic and atypical rhamnose-positive strains of Yersinia pestis","volume":"603","author":"Anisimov","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2666-5247(20)30126-9","article-title":"Protecting intubated patients from the threat of antimicrobial resistant infections with monoclonal antibodies","volume":"1","author":"Baker","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-319-72077-7_10","article-title":"Engineering Antibodies for the Treatment of Infectious Diseases","volume":"1053","author":"Fan","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Khan, A.A., Manzoor, K.N., Sultan, A., Saeed, M., Rafique, M., Noushad, S., Talib, A., Rentschler, S., and Deigner, H.P. (2021). Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020859"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S1473-3099(17)30647-3","article-title":"Plague in Madagascar","volume":"17","author":"Burki","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"j4595","DOI":"10.1136\/bmj.j4595","article-title":"Pneumonic plague outbreak hits cities in Madagascar","volume":"359","author":"Kmietowicz","year":"2017","journal-title":"BMJ"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/2\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:31:20Z","timestamp":1760124680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/2\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":80,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antib12020033"],"URL":"https:\/\/doi.org\/10.3390\/antib12020033","relation":{},"ISSN":["2073-4468"],"issn-type":[{"type":"electronic","value":"2073-4468"}],"subject":[],"published":{"date-parts":[[2023,5,8]]}}}